Levamlodipine besylate ((S)-Amlodipine besylate) is a potent dihydropyridine calcium channel blocker used for treating hypertension and angina due to its vasodilation effects[1].
Levamlodipine besylate/苯磺酸左氨氯地平 细胞实验
Cell Line
Concentration
Treated Time
Description
References
HK-2 cells
5 mmol/L
4 weeks
To investigate the effect of levamlodipine besylate on mitochondrial function and Ca2+ concentration in HK-2 cells under Wnt5a overexpression and high glucose conditions, it was found that levamlodipine besylate improved mitochondrial dysfunction and Ca2+ overload.
J Cell Mol Med. 2025 Feb;29(4):e70422
Levamlodipine besylate/苯磺酸左氨氯地平 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
DBA2/J male mice
Streptozotocin-induced diabetic nephropathy model
Oral gavage
5 mg/kg/d
Once daily for 12 weeks
To investigate the effect of levamlodipine besylate combined with losartan on renal injury and mitochondrial function in diabetic nephropathy mice, it was found that combination therapy improved renal injury and mitochondrial dysfunction more effectively than losartan alone.
J Cell Mol Med. 2025 Feb;29(4):e70422
Mice
Right unilateral common carotid arteries occlusion (rUCCAO) model
Oral
0.1 mg/kg and 0.5 mg/kg
Once a day for eight weeks
Levamlodipine besylate could reverse cognitive impairment in the VaD mouse model, reduce the latency to find the hidden platform in the MWM test, and partially restore the levels of phosphorylated CaMKII (Thr286) in the hippocampus.
搜索
